Compare KZIA & DH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KZIA | DH |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 137.2M |
| IPO Year | 2002 | 2021 |
| Metric | KZIA | DH |
|---|---|---|
| Price | $5.61 | $1.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 6 |
| Target Price | ★ $28.76 | $1.63 |
| AVG Volume (30 Days) | 167.6K | ★ 450.9K |
| Earning Date | 11-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $241,521,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.86 | $0.61 |
| 52 Week High | $17.40 | $3.00 |
| Indicator | KZIA | DH |
|---|---|---|
| Relative Strength Index (RSI) | 26.35 | 61.99 |
| Support Level | $4.86 | $1.03 |
| Resistance Level | $14.85 | N/A |
| Average True Range (ATR) | 0.68 | 0.08 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 2.75 | 55.41 |
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.